Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Guanidinopropionic Acid (GPA) has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
GPA enters muscle through the same transporter that creatine uses, and once inside it is phosphorylated to a phosphagen that regenerates ATP poorly. Taking the two together means each one reduces the other's cellular uptake, and the practical effect of GPA is to lower muscle phosphocreatine rather than raise it. The pair works against itself, so stacking them for a performance goal makes little sense.
Beta-alanine crosses membranes on beta-amino acid and taurine transporters, and guanidino analogues of the same backbone show overlapping affinity in transport studies. Where two structurally similar small molecules share a carrier, high intake of one lowers uptake of the other. This is inferred from transporter chemistry rather than measured in people taking both.
Guanidino compounds interact with the taurine transporter as well as the creatine transporter, so sustained GPA exposure can shift muscle taurine content. Any such effect is a marker of transport competition and not an outcome anyone has measured as performance or recovery. Read it as mechanistic.
GPA shares the three-carbon backbone of GABA with a guanidino group replacing the amine, and binding assays place it at inhibitory receptor sites. Whether that translates into any central effect at oral doses is untested. Nothing here supports pairing them, and the note exists so the structural overlap is on the record.
Nothing specific on file for Guanidinopropionic Acid (GPA). Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.These are the studies our verdict leans on, chosen from the 5 we read for Guanidinopropionic Acid (GPA). The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.